Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Free access | 10.1172/JCI109275

Cholic Acid Biosynthesis: THE ENZYMATIC DEFECT IN CEREBROTENDINOUS XANTHOMATOSIS

Gerald Salen, S. Shefer, F. W. Cheng, B. Dayal, A. K. Batta, and G. S. Tint

College of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, New Jersey 07103

Veterans Administration Hospital, East Orange, New Jersey 07019

Cabrini Health Care Center, New York 10003

Public Health Research Institute of The City of New York, Inc., New York 10016

Find articles by Salen, G. in: PubMed | Google Scholar

College of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, New Jersey 07103

Veterans Administration Hospital, East Orange, New Jersey 07019

Cabrini Health Care Center, New York 10003

Public Health Research Institute of The City of New York, Inc., New York 10016

Find articles by Shefer, S. in: PubMed | Google Scholar

College of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, New Jersey 07103

Veterans Administration Hospital, East Orange, New Jersey 07019

Cabrini Health Care Center, New York 10003

Public Health Research Institute of The City of New York, Inc., New York 10016

Find articles by Cheng, F. in: PubMed | Google Scholar

College of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, New Jersey 07103

Veterans Administration Hospital, East Orange, New Jersey 07019

Cabrini Health Care Center, New York 10003

Public Health Research Institute of The City of New York, Inc., New York 10016

Find articles by Dayal, B. in: PubMed | Google Scholar

College of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, New Jersey 07103

Veterans Administration Hospital, East Orange, New Jersey 07019

Cabrini Health Care Center, New York 10003

Public Health Research Institute of The City of New York, Inc., New York 10016

Find articles by Batta, A. in: PubMed | Google Scholar

College of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, New Jersey 07103

Veterans Administration Hospital, East Orange, New Jersey 07019

Cabrini Health Care Center, New York 10003

Public Health Research Institute of The City of New York, Inc., New York 10016

Find articles by Tint, G. in: PubMed | Google Scholar

Published January 1, 1979 - More info

Published in Volume 63, Issue 1 on January 1, 1979
J Clin Invest. 1979;63(1):38–44. https://doi.org/10.1172/JCI109275.
© 1979 The American Society for Clinical Investigation
Published January 1, 1979 - Version history
View PDF
Abstract

Cholic acid biosynthesis is defective in individuals with cerebrotendinous xanthomatosis (CTX) and is associated with the excretion of 5β-cholestane-3α,7α, 12α,25-tetrol, an intermediate in the 25-hydroxylation pathway of cholic acid in CTX. To define the enzymatic defect in CTX, two suspected precursors of cholic acid, namely 5β-[7β-3H]cholestane-3α,7α, 12α-triol and 5β-[24-14C]cholestane-3α,7α, 12α,24S,25-pentol were examined by both in vivo and in vitro experiments. A third precursor, 5β-[7β-3H]-cholestane-3α,7α, 12α,25-tetrol, was compared with them in vitro.

In the in vivo experiments, each one of the labeled precursors was administered intravenously to two CTX and two control subjects. In the controls, 5β-[7β-3H]cholestane-3α,7α, 12α-triol as well as 5β-[24-14C]-cholestane-3α,7α, 12α,24S,25-pentol were rapidly converted to labeled cholic acid. Maximum specific activity values were reached within 1 d after pulse labeling, followed by exponential decay of the cholic acid specific activity curves. In contrast, these two precursors differed widely when administered to two CTX patients. While 5β-[24-14C]cholestane-3α,7α, 12α,24S,25-pentol was rapidly converted to [24-14C]cholic acid and yielded identical decay curves with those obtained in the control subjects, maximum specific activity values in [7β-3H]cholic acid were much lower and peaked only on the second day after the injection of 5β-[7β-3H]cholestane-3α,7α, 12α-triol. Furthermore, an appreciable amount of 3H label was present in the 5β-cholestane-3α,7α, 12α,25-tetrol isolated from the bile of the subjects with CTX.

In the in vitro experiments, three enzymes on the 25-hydroxylation pathway of cholic acid were examined in both control and CTX subjects. The rate of the 25-hydroxylation of 5β-cholestane-3α,7α, 12α-triol in CTX patients was comparable to that in the controls. Similarly, the transformation of 5β-cholestane-3α,7α, 12α,24S,25-pentol to cholic acid, catalyzed by soluble enzymes, proceeded at approximately equal rates in CTX and in control individuals. On the other hand, the rate of 5β-cholestane-3α,7α, 12α,24S,25-pentol formation was about four times greater in the control subjects than in the CTX patients.

The results of the in vivo as well as the in vitro experiments suggest that the site of the enzymatic defect in CTX is at the 24S-hydroxylation of 5β-cholestane-3α,7α, 12α,25-tetrol. The relative deficiency of this hydroxylase in CTX patients, accompanied by the accumulation of its substrate in bile and feces, probably accounts for the subnormal production of bile acids in CTX patients.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 38
page 38
icon of scanned page 39
page 39
icon of scanned page 40
page 40
icon of scanned page 41
page 41
icon of scanned page 42
page 42
icon of scanned page 43
page 43
icon of scanned page 44
page 44
Version history
  • Version 1 (January 1, 1979): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts